Pfizer partners with BioNTech to develop vaccine for Influenza for $425M

 Pfizer partners with BioNTech to develop vaccine for Influenza for $425M

Pfizer partners with BioNTech to develop vaccine for Influenza for $425M

Shots: 

  • Pfizer is planning to pay $120M upfront along with $305M milestone payment 
  • BioNTech will also receive double-digit royalties post sales whereas, Pfizer acquires small stakes in BioNTech as part of upfront payment 
  • Pfizer plans to do further trials and commercialization of vaccines post completion of the first clinical study by BioNTech

Click here to read full press release/ article | Ref: Reuters | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post